×
About 9,383 results

ALLMedicine™ Mantle Cell Lymphoma Center

Research & Reviews  4,239 results

Identification of miRNA-34a and miRNA-155 as prognostic markers for mantle cell lymphoma.
https://doi.org/10.1177/03000605211016390
The Journal of International Medical Research; He J, Xi Y et. al.

May 24th, 2021 - MicroRNAs (miRNAs) with functional relevance have not been previously identified in mantle cell lymphoma (MCL). Here, we aimed to evaluate the relationships between miR-34a and miR-155-5p and MCL clinicopathology and prognosis. Seventy-five paraff...

Application of the Euro Clonality next-generation sequencing-based marker screening app...
https://doi.org/10.1111/bjh.17519
British Journal of Haematology; Genuardi E, Romano G et. al.

May 18th, 2021 - Minimal residual disease (MRD) determined by classic polymerase chain reaction (PCR) methods is a powerful outcome predictor in mantle cell lymphoma (MCL). Nevertheless, some technical pitfalls can reduce the rate of of molecular markers. Therefor...

Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130422
BMC Cancer; Yang X, Khoo LP et. al.

May 18th, 2021 - Significant progress has been made in the treatment outcomes of mantle cell lymphoma (MCL) since the introduction of cytarabine and rituximab in modern regimens. However, older patients may not readily tolerate these agents nor derive benefit. We ...

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evo...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128874
Nature Communications; Zhang S, Jiang VC et. al.

May 18th, 2021 - The mechanisms driving therapeutic resistance and poor outcomes of mantle cell lymphoma (MCL) are incompletely understood. We characterize the cellular and molecular heterogeneity within and across patients and delineate the dynamic evolution of t...

see more →

Guidelines  13 results

FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma
https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma
FDA

Jul 23rd, 2020 - The Food and Drug Administration granted accelerated approval to brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company), a CD19-directed genetically modified autologous T cell immunotherapy, for the treatment of adult patients with relapsed ...

KTE-X19 Demonstrates Comparable Pharmacologic, Clinical Outcomes to Approved Therapies in MCL
https://www.onclive.com/conference-coverage/asco-2020/ktex19-demonstrates-comparable-pharmacologic-clinical-outcomes-to-approved-therapies-in-mcl

May 29th, 2020 - The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial...

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
http://ascopubs.org/doi/abs/10.1200/JCO.18.00690?journalCode=jco
Gerson,J.,et al

Jan 6th, 2019 - In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our f...

Guideline for the management of mantle cell lymphoma.
https://doi.org/10.1111/bjh.15283
British Journal of Haematology; McKay P, Leach M et. al.

May 16th, 2018 - Guideline for the management of mantle cell lymphoma.|2018|McKay P,Leach M,Jackson B,Robinson S,Rule S,|therapeutic use,prevention & control,methods,pathology,therapy,

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines fo...
https://doi.org/10.1093/annonc/mdx223
Annals of Oncology : Official Journal of the European Soc... Dreyling M, Campo E et. al.

Sep 8th, 2017 - Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2017|Dreyling M,Campo E,Hermine O,Jerkeman M,Le Gouill S,|diagnosis,genetics,pathology,therapy,standards,

see more →

Drugs  25 results see all →

Clinicaltrials.gov  4,605 results

Identification of miRNA-34a and miRNA-155 as prognostic markers for mantle cell lymphoma.
https://doi.org/10.1177/03000605211016390
The Journal of International Medical Research; He J, Xi Y et. al.

May 24th, 2021 - MicroRNAs (miRNAs) with functional relevance have not been previously identified in mantle cell lymphoma (MCL). Here, we aimed to evaluate the relationships between miR-34a and miR-155-5p and MCL clinicopathology and prognosis. Seventy-five paraff...

Application of the Euro Clonality next-generation sequencing-based marker screening app...
https://doi.org/10.1111/bjh.17519
British Journal of Haematology; Genuardi E, Romano G et. al.

May 18th, 2021 - Minimal residual disease (MRD) determined by classic polymerase chain reaction (PCR) methods is a powerful outcome predictor in mantle cell lymphoma (MCL). Nevertheless, some technical pitfalls can reduce the rate of of molecular markers. Therefor...

Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130422
BMC Cancer; Yang X, Khoo LP et. al.

May 18th, 2021 - Significant progress has been made in the treatment outcomes of mantle cell lymphoma (MCL) since the introduction of cytarabine and rituximab in modern regimens. However, older patients may not readily tolerate these agents nor derive benefit. We ...

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evo...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128874
Nature Communications; Zhang S, Jiang VC et. al.

May 18th, 2021 - The mechanisms driving therapeutic resistance and poor outcomes of mantle cell lymphoma (MCL) are incompletely understood. We characterize the cellular and molecular heterogeneity within and across patients and delineate the dynamic evolution of t...

see more →

News  501 results

First CAR T-cell Therapy for Mantle Cell Lymphoma Fills Unmet Need
https://www.medscape.com/viewarticle/943428

Dec 30th, 2020 - The US Food and Drug Administration (FDA) granted accelerated approval on July 24, 2020, for the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus) for the treatment of adults with relapsed or refractory mantle cel...

CAR T for All R/R DLBCL Patients: The Jury Is Still Out
https://www.medscape.com/viewarticle/939947

Oct 27th, 2020 - Is it time to consider chimeric antigen receptor (CAR) T-cell therapy for all relapsed/refractory diffuse large B-cell lymphoma patients? Maybe not, according to Andrew Zelenetz, MD, PhD. CAR T-cell therapy has demonstrated activity in relapsed/re...

EMA OKs First CAR T-Cell Therapy for Mantle Cell Lymphoma
https://www.staging.medscape.com/viewarticle/939270

Oct 15th, 2020 - The European Medicines Agency (EMA) today recommended granting conditional marketing authorization to KTE-X19 (Tecartus), making it the first approved chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed...

EMA OKs First CAR T-Cell Therapy for Mantle Cell Lymphoma
https://www.medscape.com/viewarticle/939270

Oct 15th, 2020 - The European Medicines Agency (EMA) today recommended granting conditional marketing authorization to KTE-X19 (Tecartus), making it the first approved chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed...

Mantle Cell Lymphoma: Identifying Patients With Indolent Disease
https://www.staging.medscape.com/viewarticle/937175

Sep 9th, 2020 - Dr Eduardo Sotomayor Mantle cell lymphoma (MCL) can run the gamut from an indolent to aggressive disease, and identifying biomarkers is key in determining which patients should follow a watch-and-wait strategy and which should receive aggressive t...

see more →